NAD+ has become one of the most discussed molecules in longevity medicine. It appears in research journals, health podcasts, and clinical wellness programs with growing frequency — often described as central to healthy aging, metabolic function, and cellular longevity.
But what is NAD+ actually? What does the science say, and what doesn't it say? This article provides a clinician-reviewed explanation of NAD+ biology, the evidence behind supplementation, and how individualized clinical protocols are designed for patients considering NAD+ therapy.
Clinical note: NAD+ precursor compounds are dietary supplements, not FDA-approved drugs. Their use in clinical wellness protocols represents an evidence-adjacent application. This article is for educational purposes and does not constitute medical advice.
NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme — a molecule that assists enzymes in carrying out their functions — found in every living cell of the human body. It is one of the most abundant molecules in cellular biology and is involved in hundreds of enzymatic reactions.
NAD+ plays two primary roles in cellular function:
The scientific interest in NAD+ as it relates to aging stems primarily from one well-established fact: NAD+ levels decline significantly with age. By age 50, circulating NAD+ levels are estimated to be approximately half of what they were at age 20. By age 80, levels may be as low as 1-10% of youthful concentrations.
This decline is not merely a passive byproduct of aging. Research suggests it plays an active causal role in a number of age-related biological changes.
Mitochondria — the organelles responsible for producing ATP — require NAD+ to function efficiently. As NAD+ levels fall with age, mitochondrial function deteriorates. Cells produce less energy, accumulate more reactive oxygen species (free radicals), and become less capable of maintaining normal physiological function.
This mitochondrial decline is visible at the clinical level as reduced physical energy, diminished exercise capacity, slower recovery, and the generalized fatigue that many people associate with aging. Supporting NAD+ levels is one mechanism through which mitochondrial function may be supported.
DNA damage accumulates continuously throughout life — from oxidative stress, UV exposure, environmental toxins, and normal metabolic processes. The primary enzymes responsible for repairing this damage are PARPs (poly ADP-ribose polymerases), which consume NAD+ in the repair process.
As NAD+ levels decline with age, PARP activity — and therefore DNA repair capacity — is compromised. Accumulating unrepaired DNA damage contributes to cellular dysfunction, accelerated aging, and increased cancer risk. This is one of the primary mechanistic arguments for maintaining NAD+ levels as a longevity intervention.
Sirtuins are a family of seven proteins (SIRT1-7) that regulate an extraordinarily wide range of cellular functions — gene expression, inflammation, metabolism, stress responses, and aging-associated pathways. They are often referred to as longevity proteins because of their consistent association with extended lifespan in animal models.
Sirtuins are NAD+-dependent. They cannot function without an adequate supply of NAD+. When NAD+ levels fall, sirtuin activity falls with it. This has downstream effects on mitochondrial biogenesis, inflammation regulation, insulin sensitivity, and cellular aging processes.
NAD+ itself cannot be directly administered in a clinically practical way because it is poorly absorbed when taken orally. Instead, clinical protocols use precursor compounds — molecules that the body converts to NAD+ through established biosynthesis pathways.
NMN is a direct precursor to NAD+ — one step removed in the biosynthesis pathway. Human clinical trials have demonstrated that oral NMN supplementation measurably increases blood NAD+ levels. Studies in older adults have shown improvements in muscle function, walking speed, and metabolic markers. NMN is available in oral and injectable forms.
NR is another NAD+ precursor that is converted to NMN and then to NAD+ within cells. It has a well-established safety profile and has been studied extensively in human trials. Multiple studies have confirmed that NR supplementation increases blood NAD+ levels, with some trials showing improvements in cardiovascular and metabolic markers.
A recurring question in NAD+ research is whether orally-administered precursors actually reach target tissues in therapeutically meaningful amounts. The evidence suggests they do reach the bloodstream and increase circulating NAD+ — but the degree to which this translates to increased intracellular NAD+ in specific tissues (muscle, brain, liver) remains an active area of research.
This is one reason why injectable forms of NAD+ precursors have attracted clinical interest — subcutaneous administration bypasses some of the absorption limitations of oral supplementation. At SEVEN, NAD+ protocols are individually designed by licensed providers based on patient goals and clinical profile, with the form of administration determined on an individual basis.
The honest summary of the NAD+ evidence base is: promising but early. Animal studies — particularly in mice — have shown dramatic results from NAD+ precursor supplementation including reversal of age-related muscle decline, improved mitochondrial function, and extended lifespan. These findings are what generated the enormous scientific and public interest in NAD+.
Human clinical trials are more limited in scope and duration but have demonstrated:
What has not been demonstrated in humans — at least not yet — is the dramatic lifespan extension observed in animal models. This is an important distinction. The enthusiasm around NAD+ is based on a compelling mechanistic rationale and positive but preliminary clinical data, not a completed evidence base.
A clinician's job is to apply this evidence honestly — acknowledging what it shows and what it doesn't, designing protocols that are individually appropriate, and monitoring outcomes over time. That is the approach SEVEN takes with all of our programs.
One of the most compelling clinical connections in NAD+ research is its relationship to metabolic health. NAD+ is directly involved in the metabolic pathways that regulate insulin sensitivity, fat metabolism, and mitochondrial energy production — all central components of metabolic health.
Research has shown that NAD+ levels are reduced in states of metabolic dysfunction — including obesity and type 2 diabetes — and that improving NAD+ levels can improve insulin sensitivity and metabolic markers in animal models. Early human data suggests similar possibilities, though the evidence base requires continued development.
This metabolic connection is part of why NAD+ programs at SEVEN are framed within a broader metabolic health context — not as standalone supplementation, but as one component of an individually designed clinical protocol.
In clinical longevity and metabolic health protocols, NAD+ therapy is frequently considered alongside sermorelin — a synthetic analog of growth hormone-releasing hormone. The rationale for this combination is mechanistic: both interventions target aspects of the age-related physiological decline that converge on energy, body composition, and cellular function.
Sermorelin supports growth hormone production through the body's natural pituitary mechanisms, with downstream effects on body composition, sleep quality, and physical performance. NAD+ supports the cellular energy and repair pathways that underlie many of the same physiological processes.
Whether and how these protocols are combined is determined by individual clinical evaluation. Not every patient is a candidate for both, and the design of any combination protocol requires careful provider review.
SEVEN offers clinician-guided NAD+ programs as part of our metabolic health and longevity platform. All protocols are individually designed by licensed providers. Join early access to be notified when enrollment opens.
Learn About Our Program →